Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 2/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | NAAA | Q02083 | 2/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | CYP19A1 | P11511 | 4/20 | 0.36 |
| ▸ | CA12 | O43570 | 2/20 | 0.35 |
| ▸ | CA1 | P00915 | 2/20 | 0.35 |
| ▸ | CA2 | P00918 | 2/20 | 0.35 |
| ▸ | CA9 | Q16790 | 2/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | MMP1 | P03956 | 1/20 | 0.31 |
| ▸ | MMP9 | P14780 | 1/20 | 0.31 |
| ▸ | MMP12 | P39900 | 1/20 | 0.31 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.31 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.31 |
| ▸ | FABP7 | O15540 | 1/20 | 0.30 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.30 |
| ▸ | STS | P08842 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1439733 | 0.98 | EPHX1 (0.44) | EPHX1HTTNAAACYP2C19CYP19A1 | |
| SCHEMBL188404 | 0.98 | EPHX1 (0.44) | EPHX1HTTNAAACYP2C19CYP19A1 | |
| SCHEMBL697833 | 0.96 | EPHX1 (0.37) | EPHX1HTTNAAACYP2C19CYP19A1 | |
| SCHEMBL9034845 | 0.91 | — | — | |
| SCHEMBL5245472 | 0.83 | EPHX1 (0.39) | EPHX1HTTNAAACYP2C19CYP19A1 | |
| SCHEMBL1497921 | 0.82 | L3MBTL1 (0.35) | L3MBTL1 | |
| SCHEMBL8579936 | 0.82 | EPHX1 (0.42) | EPHX1HTTNAAACYP2C19CYP19A1 | |
| SCHEMBL1559459 | 0.82 | EPHX1 (0.42) | EPHX1HTTNAAACYP2C19CYP19A1 | |
| SCHEMBL4314580 | 0.80 | NAAA (0.39) | EPHX1HTTNAAACYP2C19CYP19A1 | |
| SCHEMBL17625372 | 0.80 | EPHX1 (0.42) | EPHX1HTTNAAACYP2C19CYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3313851-A1 | NEW HYDROXYESTER DERIVATIVES, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | Les Laboratoires Servier (FR) | 2018-05-02 | — | — | EP | disclosed |
| WO-2016207225-A1 | NEW HYDROXYESTER DERIVATIVES, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | LES LABORATOIRES SERVIER (FR) | 2016-12-29 | — | — | WO | disclosed |
| EP-2423199-A1 | Substituted imidazoles and their use as pesticides | Pfizer Limited (GB) | 2012-02-29 | — | — | EP | disclosed |
| EP-2320732-A2 | SUBSTITUTED IMIDAZOLE COMBINATIONS | Pfizer Inc. (US) | 2011-05-18 | — | — | EP | disclosed |
| US-7825149-B2 | Substituted imidazoles | PFIZER LIMITED (GB) | 2010-11-02 | — | — | US | disclosed |
| WO-2010020896-A2 | SUBSTITUTED IMIDAZOLE COMBINATIONS | PFIZER INC. (US) | 2010-02-25 | — | — | WO | disclosed |
| US-20100041712-A1 | SUBSTITUTED IMIDAZOLE COMBINATIONS | PFIZER INC. (US) | 2010-02-18 | — | — | US | disclosed |
| US-20090312326-A1 | SUBSTITUTED IMIDAZOLES | PFIZER LIMITED (GB) | 2009-12-17 | — | — | US | disclosed |
| WO-2009136965-A1 | COMPOSITIONS AND METHODS COMPRISING CAPURAMYCIN ANALOGUES | SEQUELLA, INC. (US) | 2009-11-12 | — | — | WO | disclosed |
| US-7592362-B2 | Substituted imidazoles | PFIZER LIMITED (GB) | 2009-09-22 | — | — | US | disclosed |
| WO-1999054290-A1 | INHIBITORS OF NEURAMINIDASES | ABBOTT LABORATORIES (US) | 1999-10-28 | — | — | WO | disclosed |
| WO-1999054299-A1 | PYRROLIDINES AS INHIBITORS OF NEURAMINIDASES | ABBOTT LABORATORIES (US) | 1999-10-28 | — | — | WO | disclosed |
| EP-0763053-A4 | STEROID DERIVATIVES FOR TREATMENT OF 5 ALPHA REDUCTASE | SMITHKLINE BEECHAM CORP (US) | 1998-09-09 | — | — | EP | disclosed |
| EP-0763053-A1 | STEROID DERIVATIVES FOR TREATMENT OF 5 ALPHA REDUCTASE | SMITHKLINE BEECHAM CORPORATION (US) | 1997-03-19 | — | — | EP | disclosed |
| EP-0721454-A1 | NEW PYRAZOLE DERIVATIVES AS ANGIOTENSIN II ANTAGONIST | J. URIACH & CIA. S.A. (ES) | 1996-07-17 | — | — | EP | disclosed |
| WO-1995033761-A1 | STEROID DERIVATIVES FOR TREATMENT OF 5 ALPHA REDUCTASE | SMITHKLINE BEECHAM CORPORATION (US) | 1995-12-14 | — | — | WO | disclosed |
| US-5475114-A | Angiotensin-11 antagonist; therapeutical agent used for treating hypertension and chronic heart failure | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 1995-12-12 | — | — | US | disclosed |
| EP-0646584-A1 | PYRAZOLOTRIAZOLE DERIVATIVE | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 1995-04-05 | — | — | EP | disclosed |
| US-5091382-A | CEPHALOSPORIN DERIVATIVES | HOECHST AKTIENGESELLSCHAFT (DE) | 1992-02-25 | — | — | US | disclosed |
| EP-0337637-A1 | 2-(Heterocyclylthio)carbapenem derivatives their preparation and their use as antibiotics | Sankyo Company Limited (JP) | 1989-10-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090312326-A1 | SUBSTITUTED IMIDAZOLES | ABL1, TYR, CYP3A4 | EPHX1 1428/4885HTT 1110/4885NAAA 1565/4885 |
| US-20100041712-A1 | SUBSTITUTED IMIDAZOLE COMBINATIONS | ING2, IGFBP2, IGFBP1 | EPHX1 4182/4885HTT 3979/4885NAAA 2421/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.